vs
Side-by-side financial comparison of ADAMAS TRUST, INC. (ADAM) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $43.2M, roughly 1.7× ADAMAS TRUST, INC.). On growth, ADAMAS TRUST, INC. posted the faster year-over-year revenue change (61.6% vs 27.7%). ADAMAS TRUST, INC. produced more free cash flow last quarter ($125.9M vs $14.4M). Over the past eight quarters, ADAMAS TRUST, INC.'s revenue compounded faster (55.5% CAGR vs 31.3%).
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
ADAM vs PBYI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $43.2M | $75.5M |
| Net Profit | $53.5M | — |
| Gross Margin | — | 69.3% |
| Operating Margin | — | 22.7% |
| Net Margin | 124.0% | — |
| Revenue YoY | 61.6% | 27.7% |
| Net Profit YoY | 270.5% | — |
| EPS (diluted) | $0.45 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $43.2M | $75.5M | ||
| Q3 25 | $36.6M | $54.5M | ||
| Q2 25 | $36.4M | $52.4M | ||
| Q1 25 | $33.1M | $46.0M | ||
| Q4 24 | $26.7M | $59.1M | ||
| Q3 24 | $20.2M | $80.5M | ||
| Q2 24 | $19.0M | $47.1M | ||
| Q1 24 | $17.9M | $43.8M |
| Q4 25 | $53.5M | — | ||
| Q3 25 | $44.8M | $8.8M | ||
| Q2 25 | $8.5M | $5.9M | ||
| Q1 25 | $42.2M | $3.0M | ||
| Q4 24 | $-31.4M | — | ||
| Q3 24 | $42.8M | $20.3M | ||
| Q2 24 | $-15.6M | $-4.5M | ||
| Q1 24 | $-57.9M | $-4.8M |
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
| Q4 25 | — | 22.7% | ||
| Q3 25 | — | 17.6% | ||
| Q2 25 | 11.7% | 12.7% | ||
| Q1 25 | — | 8.7% | ||
| Q4 24 | -119.0% | 22.6% | ||
| Q3 24 | — | 27.4% | ||
| Q2 24 | -124.7% | -4.6% | ||
| Q1 24 | -448.8% | -5.3% |
| Q4 25 | 124.0% | — | ||
| Q3 25 | 122.5% | 16.2% | ||
| Q2 25 | 23.4% | 11.2% | ||
| Q1 25 | 127.4% | 6.5% | ||
| Q4 24 | -117.5% | — | ||
| Q3 24 | 211.7% | 25.2% | ||
| Q2 24 | -81.9% | -9.6% | ||
| Q1 24 | -324.1% | -11.0% |
| Q4 25 | $0.45 | $0.26 | ||
| Q3 25 | $0.36 | $0.17 | ||
| Q2 25 | $-0.04 | $0.12 | ||
| Q1 25 | $0.33 | $0.06 | ||
| Q4 24 | $-0.46 | $0.40 | ||
| Q3 24 | $0.36 | $0.41 | ||
| Q2 24 | $-0.29 | $-0.09 | ||
| Q1 24 | $-0.75 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $210.3M | $97.5M |
| Total DebtLower is stronger | $735.8M | $22.7M |
| Stockholders' EquityBook value | $1.4B | $130.3M |
| Total Assets | $12.6B | $216.3M |
| Debt / EquityLower = less leverage | 0.52× | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $210.3M | $97.5M | ||
| Q3 25 | $185.3M | $94.4M | ||
| Q2 25 | $160.4M | $96.0M | ||
| Q1 25 | $177.1M | $93.2M | ||
| Q4 24 | $167.4M | $101.0M | ||
| Q3 24 | $195.1M | $96.7M | ||
| Q2 24 | $235.5M | $96.8M | ||
| Q1 24 | $226.9M | $107.2M |
| Q4 25 | $735.8M | $22.7M | ||
| Q3 25 | $766.6M | $34.0M | ||
| Q2 25 | $653.0M | $45.3M | ||
| Q1 25 | $654.4M | $56.7M | ||
| Q4 24 | $573.2M | $68.0M | ||
| Q3 24 | $699.4M | $79.3M | ||
| Q2 24 | $800.7M | $90.7M | ||
| Q1 24 | $1.0B | $102.0M |
| Q4 25 | $1.4B | $130.3M | ||
| Q3 25 | $1.4B | $115.3M | ||
| Q2 25 | $1.4B | $104.7M | ||
| Q1 25 | $1.4B | $97.1M | ||
| Q4 24 | $1.4B | $92.1M | ||
| Q3 24 | $1.4B | $71.1M | ||
| Q2 24 | $1.4B | $48.5M | ||
| Q1 24 | $1.5B | $51.0M |
| Q4 25 | $12.6B | $216.3M | ||
| Q3 25 | $12.4B | $202.9M | ||
| Q2 25 | $10.6B | $194.9M | ||
| Q1 25 | $10.0B | $196.2M | ||
| Q4 24 | $9.2B | $213.3M | ||
| Q3 24 | $8.9B | $220.7M | ||
| Q2 24 | $8.2B | $205.0M | ||
| Q1 24 | $7.4B | $214.1M |
| Q4 25 | 0.52× | 0.17× | ||
| Q3 25 | 0.55× | 0.30× | ||
| Q2 25 | 0.47× | 0.43× | ||
| Q1 25 | 0.47× | 0.58× | ||
| Q4 24 | 0.41× | 0.74× | ||
| Q3 24 | 0.48× | 1.12× | ||
| Q2 24 | 0.56× | 1.87× | ||
| Q1 24 | 0.67× | 2.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $134.0M | $14.4M |
| Free Cash FlowOCF − Capex | $125.9M | $14.4M |
| FCF MarginFCF / Revenue | 291.6% | 19.1% |
| Capex IntensityCapex / Revenue | 18.9% | 0.0% |
| Cash ConversionOCF / Net Profit | 2.50× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $134.0M | $14.4M | ||
| Q3 25 | $6.9M | $9.7M | ||
| Q2 25 | $39.2M | $14.1M | ||
| Q1 25 | $25.8M | $3.6M | ||
| Q4 24 | $14.1M | $15.6M | ||
| Q3 24 | $-922.0K | $11.0M | ||
| Q2 24 | $-993.0K | $1.0M | ||
| Q1 24 | $-13.1M | $11.2M |
| Q4 25 | $125.9M | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | $-10.6M | $15.6M | ||
| Q3 24 | $-8.6M | $11.0M | ||
| Q2 24 | $-8.6M | $1.0M | ||
| Q1 24 | $-19.1M | — |
| Q4 25 | 291.6% | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | -39.6% | 26.4% | ||
| Q3 24 | -42.3% | 13.7% | ||
| Q2 24 | -44.9% | 2.1% | ||
| Q1 24 | -107.0% | — |
| Q4 25 | 18.9% | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | 92.3% | 0.0% | ||
| Q3 24 | 37.7% | 0.0% | ||
| Q2 24 | 39.7% | 0.0% | ||
| Q1 24 | 33.5% | 0.0% |
| Q4 25 | 2.50× | — | ||
| Q3 25 | 0.15× | 1.10× | ||
| Q2 25 | 4.59× | 2.41× | ||
| Q1 25 | 0.61× | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.02× | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADAM
| Other | $19.6M | 45% |
| Constructive Loans LLC | $14.4M | 33% |
| Multifamily | $9.1M | 21% |
PBYI
Segment breakdown not available.
